Kevin Starr plans to resign as director of Alnylam Pharmaceuticals Inc., effective March 31.
The decision is not as a result of any disagreement with the company or any matter relating to its operations, policies or practices, Alnylam said in a securities filing.
Cambridge, Mass.-based Alnylam Pharmaceuticals is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics based on RNA interference.
